BridgeMD
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
EU CTIS ID: 2023-507041-28-00
What this study is testing
Evaluate the incidence and severity of late-onset targeted AEs/serious AEs (SAEs) suspected to be possibly related to gene-modified cells, including neurological disorders, autoimmune disorders, hematological disorders, serious infections, and new malignancies. Evaluate the growth, development, and sexual maturity of pediatric and adolescent subjects treated with gene-modified cells
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The subject must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent or discontinued the parent study, and must have completed the minimum duration of follow-up assessments in the parent study, as applicable.
- The subject must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted.
- In the investigator’s judgment, the subject must be willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation.
You likely can't join if
- There are no specific exclusion criteria for this study.
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- Israel
- Switzerland
- United States
- Australia
- Canada
- Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; Israel; Switzerland; United States; Australia; Canada and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.